Insight Molecular Diagnostics Inc. Fair Value of Assets Acquired
Insight Molecular Diagnostics Inc. (IMDX) reported Fair Value of Assets Acquired of $209.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2019-04-01.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:FairValueOfAssetsAcquired · last filed 2019-04-01
- Insight Molecular Diagnostics Inc. fair value of assets acquired for fiscal 2018 was $209.00K, a 45.14% decline from fiscal 2017.
- Insight Molecular Diagnostics Inc. fair value of assets acquired for fiscal 2017 was $381.00K.
| Period end | Fair Value of Assets Acquired 12 month |
|---|---|
| 2018-12-31 | $209.00K 10-K · filed 2019-04-01 |
| 2017-12-31 | $381.00K 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |